2017
DOI: 10.1016/s1474-4422(16)30292-7
|View full text |Cite|
|
Sign up to set email alerts
|

Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

6
125
0
8

Year Published

2018
2018
2022
2022

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 139 publications
(139 citation statements)
references
References 32 publications
6
125
0
8
Order By: Relevance
“…Notably, in this study, seizure freedom rates were calculated using the full FAS not just patients completing treatment. These results are consistent with those from SP993, where 73.6% of newly diagnosed epilepsy patients treated with lacosamide monotherapy completed 6 months’ and 59.5% completed 12 months’ treatment without seizures 7. Smaller studies have also shown comparable seizure freedom rates 10, 11.…”
Section: Discussionsupporting
confidence: 88%
See 1 more Smart Citation
“…Notably, in this study, seizure freedom rates were calculated using the full FAS not just patients completing treatment. These results are consistent with those from SP993, where 73.6% of newly diagnosed epilepsy patients treated with lacosamide monotherapy completed 6 months’ and 59.5% completed 12 months’ treatment without seizures 7. Smaller studies have also shown comparable seizure freedom rates 10, 11.…”
Section: Discussionsupporting
confidence: 88%
“…Its efficacy as monotherapy in patients with focal seizures has been demonstrated in two double‐blind randomized trials; a head‐to‐head non‐inferiority trial of lacosamide vs the continuous‐release (CR) formulation of carbamazepine used for EU approval (SP993)7; and a historical‐controlled, conversion to monotherapy trial (SP902) for US approval 8. In the SP993 non‐inferiority trial in patients with newly diagnosed epilepsy, 73.6% of lacosamide‐treated and 69.7% of carbamazepine‐CR‐treated patients (Full Analysis Set) completed 6 months on last evaluated dose without a seizure.…”
Section: Introductionmentioning
confidence: 99%
“…After excluding duplicates (1213) and reading title and abstracts, 14 RCTs were initially considered. 17,19 The following comparisons were included in the RCTs: phenytoin (PHT) vs valproic acid (VPA), 13 carbamazepine-immediate release (CBZ-IR) vs lamotrigine (LTG) vs gabapentin (GBP), 14 carbamazepine-controlled release (CBZ-CR) vs LTG vs levetiracetam (LEV), 15 LEV vs VPA and LEV vs CBZ-CR, 16 and CBZ-CR vs lacosamide (LCM). Hence, five RCTs were included (Figure 1), which recruited 1425 patients with newly diagnosed epilepsy.…”
Section: Resultsmentioning
confidence: 99%
“…Four trials [17][18][19][20] were included in the review, all of which were included in the meta-analysis ( Figure 1). Four trials [17][18][19][20] were included in the review, all of which were included in the meta-analysis ( Figure 1).…”
Section: Results Of the Searchmentioning
confidence: 99%
“…[17][18][19] Details of the included studies and participants are given in Tables 1 and Table S1, respectively. The studies included 2856 participants according to the ITT, 1445 for CBZ-CR and 1411 for the comparative AEDs.…”
Section: Characteristics Of the Included Studiesmentioning
confidence: 99%